| scholarly article | Q13442814 |
| P2093 | author name string | Zhimin Li | |
| John A Copland | |||
| Yushi Qiu | |||
| Han W Tun | |||
| Thomas Mehrling | |||
| P2860 | cites work | Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair | Q26863429 |
| Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma | Q27013785 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models | Q28535138 | ||
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 | ||
| Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma | Q29617568 | ||
| A randomized trial of bevacizumab for newly diagnosed glioblastoma | Q30410163 | ||
| Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma | Q33343780 | ||
| Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study | Q33383828 | ||
| Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma | Q33394023 | ||
| Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. | Q33416502 | ||
| Epidemiology of primary CNS lymphoma | Q33880458 | ||
| Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. | Q34171631 | ||
| The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications | Q35029409 | ||
| Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer | Q35079955 | ||
| Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery | Q35086666 | ||
| Age, gender, and racial differences in incidence and survival in primary CNS lymphoma | Q35620605 | ||
| CNS metastases in breast cancer | Q35874807 | ||
| Treatment of Breast Cancer Brain Metastases | Q36057858 | ||
| Optimal role of temozolomide in the treatment of malignant gliomas. | Q36113030 | ||
| A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. | Q36337623 | ||
| Standards of care for treatment of recurrent glioblastoma--are we there yet? | Q36500401 | ||
| How I treat CNS lymphomas | Q37215118 | ||
| Personalized treatment strategies in glioblastoma: MGMT promoter methylation status | Q37221207 | ||
| The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment. | Q38017232 | ||
| Glioblastoma: from molecular pathology to targeted treatment | Q38128382 | ||
| Metastatic behavior of breast cancer subtypes | Q38416421 | ||
| Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells. | Q38862949 | ||
| Adult Glioblastoma | Q39391227 | ||
| Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels | Q39556740 | ||
| How I treat primary CNS lymphoma | Q39746438 | ||
| The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101. | Q40933121 | ||
| Malignant Lymphomas of the Nervous System | Q42447293 | ||
| Phase I/II Trial of Vorinostat Combined with Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma: Final Results of Alliance N0874/ABTC 02. | Q42696115 | ||
| Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma | Q46796397 | ||
| Primary CNS Lymphoma. | Q51841565 | ||
| Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series. | Q53064246 | ||
| Treatment and prognosis of brain metastases from breast cancer | Q81235660 | ||
| P433 | issue | 46 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | brain tumor | Q233309 |
| P304 | page(s) | 28155-28164 | |
| P577 | publication date | 2018-06-15 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models | |
| P478 | volume | 9 |
| Q90481686 | Supportive roles of brain macrophages in CNS metastases and assessment of new approaches targeting their functions | cites work | P2860 |
Search more.